Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma
- Xu-Monette, Z.Y.
- Li, L
- Byrd, J.C.
- Jabbar, K.J.
- Manyam, G.C.
- Winde, C. Maria de
- Brand, M. van den
- Tzankov, A.
- Visco, C.
- Wang, J
- Dybkaer, K.
- Chiu, A.
- Orazi, A.
- Zu, Y.
- Bhagat, G.
- Richards, K.L.
- Hsi, E.D.
- Choi, W.W.
- Huh, J.
- Ponzoni, M.
- Ferreri, A.J.
- Moller, M.B.
- Parsons, B.M.
- Winter, J.N.
- Wang, M.
- Hagemeister, F.B.
- Piris, M.A.
- Krieken, J.H. van
- Medeiros, L.J.
- Li, Y.
- Spriel, A.B. van
- Young, K.H.
DOIAbstract
CD37 (tetraspanin TSPAN26) is a B-cell surface antigen widely expressed on mature B cells. CD37 is involved in immune regulation and tumor suppression but its function has not been fully elucidated. We assessed CD37 expression in de novo diffuse large B-cell lymphoma (DLBCL), and investigated its clinical and biologic significance in 773 patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and 231 patients treated with CHOP. We found that CD37 loss (CD37-) in approximately 60% of DLBCL patients showed significantly decreased survival after R-CHOP treatment, independent of the International Prognostic Index (IPI), germinal center B-cell-like (GCB)/activated B-cell-like (ABC) cell of origin,...
Add to ORKG